Meilleure Health International Industry Group Ltd
Meilleure Health International Industry Group Ltd operates in the pharmaceuticals industry, focusing on the development and distribution of healthcare products.
Business. Meilleure Health International Industry Group Ltd (2327.HK) is a pharmaceutical company listed on the Hong Kong Stock Exchange. The firm operates within the healthcare sector, specifically focusing on pharmaceuticals and medical research activities. It generates revenue through the sale of products. Specific details regarding operating segments and geographic presence are not provided.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Meilleure Health International Industry Group Ltd (2327.HK) is a pharmaceutical company listed on the Hong Kong Stock Exchange. The firm operates within the healthcare sector, specifically focusing on pharmaceuticals and medical research activities. It generates revenue through the sale of products. Specific details regarding operating segments and geographic presence are not provided.
The company's capital structure is characterized by a market price of 0.29 HKD per share, resulting in a market capitalization of 1,185,644,304.44 HKD. The shares outstanding are 4,088,428,636 for both basic and diluted shares, indicating no immediate dilution risk.
Profitability and return metrics are not available in the provided data, which limits the ability to compare the company's performance against industry benchmarks. The absence of detailed financial metrics such as return on invested capital (ROIC) and operating margins prevents a comprehensive assessment of the company's financial health.
Segment and geographic exposure details are not disclosed in the available data, making it difficult to assess the company's revenue concentration or geographic diversification. Without this information, it is not possible to determine the extent of the company's exposure to specific markets or product lines.
Growth trajectory data is limited, with no specific numeric deltas or revenue history provided for the current or next fiscal year. The lack of detailed outlook data hinders the ability to evaluate the company's future performance and growth potential.
Risk factors include the inability to assess liquidity risk due to the absence of balance-sheet inputs and no going-concern language in the source documents. The dilution risk is currently assessed as low, with no immediate pressure from dilution sources.
Recent events and filings are not detailed in the provided data, which limits the ability to assess the company's recent performance or strategic direction. The lack of transcripts or recent filings prevents a deeper understanding of the company's current status.
- The company has a market capitalization of 1,185,644,304.44 HKD with no immediate dilution risk.
- Detailed financial metrics such as ROIC and operating margins are not available, limiting the ability to assess profitability.
- Segment and geographic exposure details are not disclosed, making it difficult to evaluate revenue concentration.
- Growth trajectory data is limited, with no specific numeric deltas or revenue history provided.
- Liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.
- Recent events and filings are not detailed, limiting the understanding of the company's current status.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue HK$129.3M, +7,8% YoY; Operating income +33,2% YoY.
- ▍Revenue HK$129.3M, +7,8% YoY
- ▍Operating income +33,2% YoY
- ▍Net income +129,1% YoY
- ▍Free cash flow −222,4% YoY
- ▍Net margin 31.6%
Revenue HK$119.9M, −52,6% YoY; Operating income −50,9% YoY.
- ▍Revenue HK$119.9M, −52,6% YoY
- ▍Operating income −50,9% YoY
- ▍Net income −70,5% YoY
- ▍Free cash flow −64,2% YoY
- ▍Net margin 14.9%
Revenue HK$253.0M; Operating income HK$105.2M.
- ▍Revenue HK$253.0M
- ▍Operating income HK$105.2M
- ▍Net margin 23.8%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Meilleure Health International Industry Group Ltd Market data — financials · 2026-05-26
Ownership & reference
Leadership
- Wen Chuan ZhouChief Executive Officer, Executive Director